SSTR2、ADAM-12、FLI-1在小细胞肺癌组织中的表达及临床意义  

Expression and clinical significance of SSTR2,ADAM-12 and FLI-1 in small cell lung cancer tissue

作　　者：王猛 邓娟 栾雪静[1] 姜丽莉 Wang Meng;Deng Juan;Luan Xuejing;Jiang Lili(Department of Respiratory Medicine,Haiyang People's Hospital,Haiyang 265100,Shandong Province,China)

机构地区：[1]海阳市人民医院呼吸内科,海阳265100

出　　处：《中国基层医药》2023年第4期601-606,共6页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探究生长抑素受体2(SSTR2)、去整合素金属蛋白酶12(ADAM-12)、白血病病毒整合1(FLI-1)在小细胞肺癌中的表达及临床意义。方法选取海阳市人民医院2020年1月至2021年1月收治的小细胞肺癌患者82例为观察对象。患者均行根治性手术切除,并留取小细胞肺癌组织、癌组织边缘2 cm以上癌旁组织。癌组织、癌旁组织标本SSTR2、ADAM-12、FLI-1阳性表达率通过免疫组化法进行检测。分析SSTR2、ADAM-12、FLI-1与临床特征的关系,统计小细胞肺癌患者1年生存率。结果阳性率方面,癌组织中SSTR2[79.27%(65/82)]、ADAM-12[76.83%(63/82)]、FLI-1[78.05%(64/82)]均显著高于癌旁组织[19.51%(16/82)、17.07%(14/82)、20.73%(17/82)][χ^(2)=58.57、58.78、53.90,均P<0.05]。SSTR2、ADAM-12、FLI-1与淋巴结转移、临床分期、组织侵犯、肿瘤大小、组织学分级呈正相关(均P<0.05)。将性别、年龄等因素控制后,SSTR2、ADAM-12、FLI-1与淋巴结转移、临床分期、组织侵犯、肿瘤大小、组织学分级相关(均P<0.05)。随访1年,失访6例,76例小细胞肺癌患者1年生存率为67.11%(51/76)。SSTR2、ADAM-12、FLI-1阳性表达患者生存率低于SSTR2、ADAM-12、FLI-1阴性表达患者(χ^(2)=3.93、6.43、7.52,均P<0.05)。结论SSTR2、ADAM-12、FLI-1在小细胞肺癌中呈高表达,联合检测有利于小细胞肺癌患者预后、病情的评估,本研究具备一定创新性和科学性。Objective To investigate the expression and clinical significance of somatostatin receptor 2(SSTR2),a disintegrin and metalloproteinase-12(ADAM-12),and friend leukemia virus integration-1(FLI-1)in small cell lung cancer tissue.Methods Eighty-two patients with small cell lung cancer who received treatment in Haiyang People's Hospital from January 2020 to January 2021 were included in this study.All patients underwent radical surgical resection.Small cell lung cancer tissues and adjacent tissues more than 2 cm from the edge of cancer tissues were harvested.The positive expression rates of SSTR2,ADAM-12,and FLI-1 in cancer tissues and adjacent tissues were determined by immunohistochemistry.The relationship between SSTR2,ADAM-12,FLI-1,and clinical characteristics were analyzed.The 1-year survival rate of patients with small cell lung cancer was calculated.Results The positive rates of SSTR2,ADAM-12,and FLI-1 in small cell lung cancer tissue were 79.27%(65/82),76.83%(63/82),and 78.05%(64/82),respectively,which were significantly higher than 19.51%(16/82),17.07%(14/82),20.73%(17/82)in the adjacent tissue(χ^(2)=58.57,58.78,53.90,all P<0.05).SSTR2,ADAM-12,and FLI-1 were positively associated with lymph node metastasis,clinical stage,tissue invasion,tumor size,and histological grade(all P<0.05).After controlling for gender,age,and others,SSTR2,ADAM-12,and FLI-1 were associated with lymph node metastasis,clinical stage,tissue invasion,tumor size,and histological grade(all P<0.05).All patients were followed up for 1 year.Six patients were lost to follow-up.The 1-year survival rate of 76 patients with small cell lung cancer was 67.11%(51/76).The survival rate of patients with positive SSTR2,ADAM-12,and FLI-1 expression were lower than that of patients with negative SSTR2,ADAM-12,and FLI-1 expression(χ^(2)=3.93,6.43,7.52,all P<0.05).Conclusion SSTR2,ADAM-12,and FLI-1 are highly expressed in small cell lung cancer tissue.Combined detection of SSTR2,ADAM-12,and FLI-1 is conducive to the prognosis and evaluation of small cell

关 键 词：小细胞肺癌 生长抑素受体 金属蛋白酶 病毒整合 免疫组织化学 预后 早期诊断 存活 

分 类 号：R734.2[医药卫生—肿瘤]